Posted by RobertDavid on May 19, 2006, at 19:46:42
The following are a two paragraphs from an article in the Pychiatric Times. It mentions comments from Wayne Goodman, the FDA advisory committe chairperson about the development of a new drug that would be a possible competitor to EMSAM. Does anyone have any info on this drug, heard about it? Perhaps their will be a new option to EMSAM coming out. I wonder if it's an existing MAOI or ????
While the members of the advisory committee are mostly academics, 8 of the 11 members had relationships with drug companies whose products could have been affected by decisions the advisory committee made that day. Before the meeting started, Karen M. Templeton-Somers, PhD, acting executive secretary, read off a list of those members and their relationships. She noted that the advisory committee's chairperson, Wayne Goodman, MD, works for 2 employers (the University of Florida College of Medicine and the McKnight Brain Institute at the University of Florida) that have 4 separate contracts—2 with firms funded at less than $100,000 per year and 2 others with separate drug firms funded at between $100,001 and $300,000 per year.
Goodman pointed out that those relationships pertained to contracts held by other investigators in his department with a company developing a drug that would be a competitor to selegiline (Emsam), the first transdermal patch medication used for treating major depression. The committee voted to recommend Emsam's approval on the second day of that October meeting, and the FDA approved the drug on February 28, 2006. Emsam was developed by Somerset Pharmaceuticals,Inc. In December 2004, Bristol-Myers Squibb and Somerset entered into an agreement that provides Bristol-Myers Squibb with distribution rights to market Emsam.
poster:RobertDavid
thread:646057
URL: http://www.dr-bob.org/babble/20060515/msgs/646057.html